Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Autor: Kos, Z., Roblin, E., Kim, R. S., Michiels, S., Gallas, B. D., Chen, W., van de Vijver, K. K., Goel, S., Adams, S., Demaria, S., Viale, G., Nielsen, T. O., Badve, S. S., Symmans, W. F., Sotiriou, C., Rimm, D. L., Hewitt, S., Denkert, C., Loibl, S., Luen, S. J., Bartlett, J. M. S., Savas, P., Pruneri, G., Dillon, D. A., Cheang, M. C. U., Tutt, A., Hall, J. A., Kok, M., Horlings, H. M., Madabhushi, A., van der Laak, J., Ciompi, F., Laenkholm, A. -V., Bellolio, E., Gruosso, T., Fox, S. B., Araya, J. C., Floris, G., Hudecek, J., Voorwerk, L., Beck, A. H., Kerner, J., Larsimont, D., Declercq, S., Van den Eynden, G., Pusztai, L., Ehinger, A., Yang, W., Abduljabbar, K., Yuan, Y., Singh, R., Hiley, C., Bakir, M., Lazar, A. J., Naber, S., Wienert, S., Castillo, M., Curigliano, G., Dieci, M. -V., Andre, F., Swanton, C., Reis-Filho, J., Sparano, J., Balslev, E., Chen, I. -C., Stovgaard, E. I. S., Pogue-Geile, K., Blenman, K. R. M., Penault-Llorca, F., Schnitt, S., Lakhani, S. R., Vincent-Salomon, A., Rojo, F., Braybrooke, J. P., Hanna, M. G., Soler-Monso, M. T., Bethmann, D., Castaneda, C. A., Willard-Gallo, K., Sharma, A., Lien, H. -C., Fineberg, S., Thagaard, J., Comerma, L., Gonzalez-Ericsson, P., Brogi, E., Loi, S., Saltz, J., Klaushen, F., Cooper, L., Amgad, M., Moore, D. A., Salgado, R., Hyytiainen, A., Hida, A. I., Thompson, A., Lefevre, A., Gown, A., Lo, A., Sapino, A., Moreira, A. M., Richardson, A., Vingiani, A., Bellizzi, A. M., Guerrero, A., Grigoriadis, A., Garrido-Castro, A. C., Cimino-Mathews, A., Srinivasan, A., Acs, B., Singh, B., Calhoun, B., Haibe-Kans, B., Solomon, B., Thapa, B., Nelson, B. H., Ballesteroes-Merino, C., Criscitiello, C., Boeckx, C., Colpaert, C., Quinn, C., Chennubhotla, C. S., Solinas, C., Drubay, D., Sabanathan, D., Peeters, D., Zardavas, D., Hoflmayer, D., Johnson, D. B., Thompson, E. A., Perez, E., Elgabry, E. A., Blackley, E. F., Reisenbichler, E., Chmielik, E., Gaire, F., F. -I., Lu, Azmoudeh-Ardalan, F., Peale, F., Hirsch, F. R., Acosta-Haab, G., Farshid, G., Broeckx, G., Koeppen, H., Haynes, H. R., Mcarthur, H., Joensuu, H., Olofsson, H., Cree, I., Nederlof, I., Frahm, I., Brcic, I., Chan, J., Ziai, J., Brock, J., Weseling, J., Giltnane, J., Lemonnier, J., Zha, J., Ribeiro, J., Lennerz, J. K., Carter, J. M., Hartman, J., Hainfellner, J., Le Quesne, J., Juco, J. W., van den Berg, J., Sanchez, J., Cucherousset, J., Adam, J., Balko, J. M., Saeger, K., Siziopikou, K., Sikorska, K., Weber, K., Steele, K. E., Emancipator, K., El Bairi, K., Allison, K. H., Korski, K., Buisseret, L., Shi, L., Kooreman, L. F. S., Molinero, L., Estrada, M. V., Van Seijen, M., Lacroix-Triki, M., Sebastian, M. M., Balancin, M. L., Mathieu, M. -C., van de Vijver, M., Rebelatto, M. C., Piccart, M., Goetz, M. P., Preusser, M., Khojasteh, M., Sanders, M. E., Regan, M. M., Barnes, M., Christie, M., Misialek, M., Ignatiadis, M., de Maaker, M., Van Bockstal, M., Harbeck, N., Tung, N., Laudus, N., Sirtaine, N., Burchardi, N., Ternes, N., Radosevic-Robin, N., Gluz, O., Grimm, O., Nuciforo, P., Jank, P., Kirtani, P., Watson, P. H., Jelinic, P., Francis, P. A., Russell, P. A., Pierce, R. H., Hills, R., Leon-Ferre, R., de Wind, R., Shui, R., Leung, S., Tabbarah, S., Souza, S. C., O'Toole, S., Swain, S., Dudgeon, S., Willis, S., Ely, S., Bedri, S., Irshad, S., Liu, S., Hendry, S., Bianchi, S., Braganca, S., Paik, S., Luz, S., Gevaert, T., D'Alfons, T., John, T., Sugie, T., Kurkure, U., Bossuyt, V., Manem, V., Camaea, V. P., Tong, W., Tran, W. T., Wang, Y., Allory, Y., Husain, Z., Bago-Horvath, Z.

Publikováno v: npj Breast Cancer
npj Breast Cancer, Nature, 2020, 6 (1), pp.17. ⟨10.1038/s41523-020-0156-0⟩
NPJ BREAST CANCER
NPJ breast cancer, 6, 1
Dipòsit Digital de la UB
Universidad de Barcelona
npj Breast Cancer, 6(1):17. Nature Publishing Group
The International Immuno-Oncology Biomarker Working Group 2020, ' Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer ', npj Breast Cancer, vol. 6, no. 1, 17 . https://doi.org/10.1038/s41523-020-0156-0
NPJ breast cancer, 6
Kos, Z, Roblin, E, Kim, R S, Michiels, S, Gallas, B D, Chen, W, van de Vijver, K K, Goel, S, Adams, S, Demaria, S, Viale, G, Nielsen, T O, Badve, S S, Symmans, W F, Sotiriou, C, Rimm, D L, Hewitt, S, Denkert, C, Loibl, S, Luen, S J, Bartlett, J M S, Savas, P, Pruneri, G, Dillon, D A, Cheang, M C U, Tutt, A, Hall, J A, Kok, M, Horlings, H M, Madabhushi, A, van der Laak, J, Ciompi, F, Laenkholm, A-V, Bellolio, E, Gruosso, T, Fox, S B, Araya, J C, Floris, G, Hudeček, J, Voorwerk, L, Beck, A H, Kerner, J, Larsimont, D, Declercq, S, Van den Eynden, G, Pusztai, L, Ehinger, A, Singh, R, Balslev, E, Stovgaard, E I S & International Immuno-Oncology Biomarker Working Group 2020, ' Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer ', npj Breast Cancer, vol. 6, pp. 17 . https://doi.org/10.1038/s41523-020-0156-0
NPJ Breast Cancer
npj Breast Cancer, Vol 6, Iss 1, Pp 1-16 (2020)
npj Breast Cancer, 2020, 6 (1), pp.17. ⟨10.1038/s41523-020-0156-0⟩
2020, ' Pitfalls in Assessing Stromal Tumor Infiltrating Lymphocytes (sTILs) in Breast Cancer ', NPJ Breast Cancer . https://doi.org/10.1038/s41523-020-0156-0

Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4063f2cd24ffe1264c2ae53c506385ac
https://lirias.kuleuven.be/handle/123456789/655365

Novel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment.

Autor: Lubo, Idania¹ (AUTHOR) ilubo@mdanderson.org, Hernandez, Sharia¹ (AUTHOR), Wistuba, Ignacio I.¹ (AUTHOR), Solis Soto, Luisa Maren¹ (AUTHOR) lmsolis@mdanderson.org

Publikováno v: Cancers. Dec2024, Vol. 16 Issue 24, p4145. 18p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.

Autor: Taube JM; Department of Dermatology, Johns Hopkins School of Medicine, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA jtaube1@jhmi.edu., Akturk G; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York City, USA., Angelo M; Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA., Engle EL; Department of Dermatology, Johns Hopkins School of Medicine, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA., Gnjatic S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York City, USA., Greenbaum S; Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA., Greenwald NF; Department of Pathology, Stanford University School of Medicine, Palo Alto, California, USA.; Cancer Biology Program, Stanford University School of Medicine, Palo Alto, California, USA., Hedvat CV; Bristol-Myers Squibb, New York, New York City, USA., Hollmann TJ; Dermatopathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA., Juco J; Merck & Co Inc, Kenilworth, New Jersey, USA., Parra ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rebelatto MC; AstraZeneca, Gaithersburg, Maryland, USA., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA., Rodriguez-Canales J; AstraZeneca, Gaithersburg, Maryland, USA., Schalper KA; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA., Stack EC; Jounce Therapeutics Inc, Cambridge, Massachusetts, USA., Ferreira CS; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Korski K; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany., Lako A; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Rodig SJ; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Schenck E; AstraZeneca, Gaithersburg, Maryland, USA., Steele KE; AstraZeneca, Gaithersburg, Maryland, USA., Surace MJ; AstraZeneca, Gaithersburg, Maryland, USA., Tetzlaff MT; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., von Loga K; Biomedical Research Centre, Royal Marsden NHS Foundation Trust, London, UK., Wistuba II; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bifulco CB; Providence Portland Medical Center, Portland, Oregon, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 May; Vol. 8 (1).

The World of Immunotherapy Needs More Than PD-1/PD-L1—Two of the New Kids on the Block: LAG-3 and TIGIT.

Autor: Gama, João Martins^1,2 (AUTHOR) 11867@chuc.min-saude.pt, Teixeira, Paulo¹ (AUTHOR) paulocmiranda@ulscoimbra.min-saude.pt, Caetano Oliveira, Rui^3,4 (AUTHOR) rui.caetano@germanodesousa.com

Publikováno v: Onco. Sep2024, Vol. 4 Issue 3, p116-130. 15p.